QADYNA
Dead / Cancelled — Cancelled — Section 8 (as of 09 Sept 2022)
What this means for you
This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 85143129
- Registration number
- 4106454
- Mark type
- Stylized text
- Filed
- 01 Oct 2010
- Published for opposition
- 11 Jan 2011
- Registered
- 28 Feb 2012
- Attorney of record
- Richard A. Friedman
Goods and services
- Class 005 — Pharmaceuticals: Orally administered pharmaceutical preparations available by prescription only, for the treatment of a rare protein misfolding disease, namely, amyloidosis
Owner
- FoldRx Pharmaceuticals, Inc., Cambridge, MA, US
- FoldRx Pharmaceuticals, Inc., Cambridge, MA, US
- FoldRx Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 09 Sept 2022 — CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
- 28 Feb 2021 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 11 Mar 2018 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 11 Mar 2018 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 11 Mar 2018 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 20 Feb 2018 — TEAS SECTION 8 RECEIVED
- 28 Feb 2017 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 28 Feb 2012 — REGISTERED-PRINCIPAL REGISTER
- 26 Jan 2012 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 25 Jan 2012 — LAW OFFICE REGISTRATION REVIEW COMPLETED
- 23 Jan 2012 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 19 Jan 2012 — STATEMENT OF USE PROCESSING COMPLETE
- 18 Jan 2012 — USE AMENDMENT FILED
- 18 Jan 2012 — TEAS STATEMENT OF USE RECEIVED
- 02 Sept 2011 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED